Interestingly, contrary to previous studies showing that high HMGB2 expression was related to treatment resistance in vitro [27,28], here, we observed significantly better survival in patients with grade 4 diffuse astrocytomas (GBM and A4 IDHmut) treated with adjuvant chemoradiation. The gene discussed is HMGB2; the disease is diffuse astrocytoma.